metabolic research raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-05 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
A variety of serotonergic psychedelics have been assessed and found to produce neurotoxicity at high concentrations in vitro and/or high doses in vivo in rodents. These psychedelics have included DOI, 2C-B, 25B-NBOMe, 25C-NBOMe, 5-MeO-DiPT, 5-MeO-MiPT, methallylescaline (MAL), and BOD, among others. The neurotoxicity induced by the preceding psychedelics has included MDMA-like serotonergic neurotoxicity, for instance with DOI, MAL, and 5-MeO-DiPT. The neurotoxicity of psychedelics has been found to be partially blocked by serotonin 5-HT2A receptor inhibition, which was also the case with the neurotoxicity of MDMA. Besides producing neurotoxicity on their own, psychedelics have been found to potentiate the serotonergic neurotoxicity of MDMA via serotonin 5-HT2 receptor activation in rodents. DOM is known to metabolize into 2,5-DDM-DOM (2-O-,5-O-didesmethyl-DOM; 2,5-dihydroxy-4-methylamphetamine), which bears a close resemblance to 6-hydroxydopamine (6-OHDA; 2,4,5-trihydroxyphenethylamine) and has been found to be a potent neurotoxin similarly. Other related phenethylamine psychedelics may also undergo similar metabolism and form analogous potentially neurotoxic metabolites. Chronic administration of LSD has been associated with long-lasting schizophrenia-like behavioral changes in rodents, which was not blocked by serotonin 5-HT2A receptor antagonism but may instead be related to LSD's dopamine D2-like receptor agonism.
Following adverse findings of the program, WorkSafe Victoria performed an investigation. In November 2015, it convicted Essendon of two breaches of the state's Occupational Health and Safety Act for failing to provide the players with a workplace free of health risks. The club was fined $200,000 for the breaches. The handling of the investigation and prosecution by both the AFL and ASADA was criticised by some media personnel and other public figures. There were suggestions that a parliamentary inquiry should be held into the saga, but this was ruled out by Greg Hunt, Minister for Sport, in March 2017.
The emu (; Dromaius novaehollandiae) is a species of flightless bird endemic to Australia, where it is the tallest native bird. It is the only extant member of the genus Dromaius and the third-tallest living bird after its African ratite relatives, the common ostrich and Somali ostrich. The emu's native ranges cover most of the Australian mainland. The Tasmanian, Kangaroo Island and King Island subspecies became extinct after the European settlement of Australia in 1788. The emu has soft, brown feathers, a long neck, and long legs. It can grow up to 1.9 m (6 ft 3 in) in height. It is a robust bipedal runner that can travel great distances, and when necessary can sprint at 48 km/h (30 mph). It is omnivorous and forages on a variety of plants and insects, and can go for weeks without eating. It drinks infrequently, but takes in copious amounts of fresh water when the opportunity arises. Breeding takes place in May and June, and fighting among females for a mate is common. Females can mate several times and lay several clutches of eggs in one season. The male incubates the eggs; during this process he hardly eats or drinks and loses a significant amount of weight. The eggs hatch after around eight weeks, and the young are nurtured by their fathers. They reach full size after around six months, but can remain as a family unit until the next breeding season. The emu is sufficiently common to be rated as a least-concern species by the International Union for Conservation of Nature.
=== History === In January 2009, the U.S. Department of Defense announced the largest RFID award in history, a $429 million contract for DASH7 devices, to four prime contractors, namely Savi Technology, Northrop Grumman Information Technology, Unisys and Systems & Processes Engineering Corporation (SPEC). In March 2009, the DASH7 Alliance, a non-profit industry consortium to promote interoperability among DASH7-compliant devices, was announced, and as of July 2010 has more than 50 participants in 23 countries. It was meant to be similar to what the Wi-Fi Alliance does for IEEE 802.11, for wireless sensor networking. In April 2011, the DASH7 Alliance announced adoption of DASH7 Mode 2, based on the ISO 18000-7 standard that makes better use of modern silicon to achieve faster throughput, multi-hop, lower latency, better security, sensor support, and a built-in query protocol. In March 2012, the DASH7 Alliance announced that it was making the DASH7 Mode 2 specification available to non-members. In July 2013, the DASH7 Alliance announced the DASH7 Alliance Protocol Draft 0.2. In May 2015, the DASH7 Alliance publicly released v1.0 of the DASH7 Alliance Protocol. In January 2017, the DASH7 Alliance publicly released the v1.1 of the DASH7 Alliance Protocol. The version constitutes a major update of v1.0, in particular in the area of security and interoperability.
The Six Million Dollar Man is an American science fiction and action television series, running from 1973 to 1978, about a former astronaut, USAF Colonel Steve Austin, portrayed by Lee Majors. After being seriously injured in a NASA test flight crash, Austin is rebuilt (at considerable expense, hence the title of the series) with bionic implants that give him superhuman strength, speed and vision. Austin is then employed as a secret agent by a fictional American government office titled OSI. The series was based on Martin Caidin's 1972 novel Cyborg, which was the working title of the series during pre-production. Following three television films intended as pilots, which all aired in 1973, The Six Million Dollar Man television series aired on the ABC network as a regular episodic series for five seasons from 1974 to 1978. Steve Austin became a pop culture icon of the 1970s.
Sources: en.wikipedia.org
Clinical data management (CDM) is a critical process in clinical research, which leads to generation of high-quality, reliable, and statistically sound data from clinical trials. Clinical data management ensures collection, integration and availability of data at appropriate quality and cost. It also supports the conduct, management and analysis of studies across the spectrum of clinical research as defined by the National Institutes of Health (NIH). The ultimate goal of CDM is to ensure that conclusions drawn from research are well supported by the data. Achieving this goal protects public health and increases confidence in marketed therapeutics.
Overall, the adverse events attributed to JDtic were similar to those reported with placebo, except for cardiac events, such as bradycardia and ventricular tachycardia (VT), which were seen only in the JDTic group. The episodes of VT occurred in two subjects, were not sustained (NSVT), and were asymptomatic. Preclinical experiments in monkeys showed that JDTic administration resulted in a short run of NSVT. Other safety measurements, including clinical laboratory studies, 12-lead ECG, psychomotor function, and measures of mood, did not differ between group during admission or at follow-up. Overall, these results indicate that JDTic administration is associated with short lived, but detectable ventricular tachycardia in 2/6 subjects receiving the active dose. The episodes of NSVT were asymptomatic, were not seen in the majority of subjects, and sporadic. NSVT is known to occur in the general population, although at a low rate. Nonetheless, the likelihood that these cardiac events were induced by JDTic is high, given that both events occurred as a similar time following dosing, the lower incidence of sporadic VT expected in healthy subjects, and the presence of kappa receptors and dynorphin in cardiac tissue. Given the potentially serious clinical consequences of VT and concerns that individuals with cardiovascular disease may have heightened vulnerability, the decision was made by the safety board of this study that further human trials of this drug would not be ethically justified.
=== Other formulations === The original oral formulation of selegiline was developed for the treatment of depression. However, it ended up being developed and approved for the treatment of Parkinson's disease instead. In any case, oral selegiline has been widely used off-label to treat depression. The transdermal patch form of selegiline was developed and approved specifically for the treatment of depression. It was also under development for the treatment of Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), cognition disorders, and Parkinson's disease, but development for these indications was discontinued. The ODT form of selegiline was developed and licensed exclusively for the treatment of Parkinson's disease.
=== India === G. N. Singh, India's top drug regulator, said in a 2014 interview: "If I have to follow U.S. standards in inspecting facilities supplying to the Indian market, […] we will have to shut almost all of those." According to Outsourcing Pharma in 2012, 75% of counterfeit drugs supplied worldwide had some origins in India, followed by 7% from Egypt and 6% from China. In 2009, the Central Drug Standards Control Organisation (CDSCO), the drug regulatory authority of India conducted a nationwide survey, and announced that of "24,000 samples [that] were collected from all over India and tested. It was found that only 11 samples or 0.046% were spurious." In 2017 a similar survey found 3.16% of the medicines sampled were substandard and 0.0245% were fake. Those more commonly prescribed are probably more often faked. In 2017, industry body ASSOCHAM wrote in the paper "Fake and Counterfeit Drugs In India –Booming Biz" that fake drugs constitute US$4.25 billion of the total US$14–17 billion of domestic drug market. Around 25% of India's drugs are fake, counterfeit or substandard. If the fake drugs market grows at the current rate of 25%, it will cross the US$10 billion mark by 2017. Trade in fake drugs is driven caused by lack of adequate regulations, shortage of drug inspectors and a lack of lab facilities to check the purity of drugs. Other key factors include storage of spurious drugs by chemists, weaknesses in drug distribution system, lack of awareness among consumers and lack of law enforcement.
In large short-term observational studies, estrogen alone and the combination of estrogen and oral progesterone have generally not been associated with an increased risk of breast cancer. Conversely, the combination of estrogen and almost any progestin, such as medroxyprogesterone acetate or norethisterone acetate, has been associated with an increased risk of breast cancer. The only exception among progestins is dydrogesterone, which has shown similar risk to that of oral progesterone. Breast cancer risk with estrogen and progestin therapy is duration-dependent, with the risk being significantly greater with more than 5 years of exposure relative to less than 5 years. In contrast to shorter-term studies, the longer-term observations (>5 years) of the French E3N study showed significant associations of both estrogen plus oral progesterone and estrogen plus dydrogesterone with higher breast cancer risk, similarly to estrogen plus other progestogens. Oral progesterone has very low bioavailability and has relatively weak progestogenic effects. The delayed onset of breast cancer risk with estrogen plus oral progesterone is potentially consistent with a weak proliferative effect of oral progesterone on the breasts. As such, a longer duration of exposure may be necessary for a detectable increase in breast cancer risk to occur. In any case, the risk remains lower than that with most progestins.
Sources: en.wikipedia.org
== History == In 2019, Hailey Rhode Bieber began conceptualizing a cosmetics brand and filed to trademark "Bieber Beauty". It was rejected, as her husband Justin Bieber had already trademarked the name in 2010. Bieber later launched rhode skin on June 15, 2022, alongside Lauren and Michael D. Ratner, choosing the name as a direct reference to her own middle name, Rhode, after her initial "Bieber Beauty" trademark application was rejected. Rhode was funded primarily by Bieber, with investment firm One Luxury Group as a strategic partner. Its core products at launch included the Peptide Glazing Fluid, Barrier Restore Cream and Peptide Lip Treatment. Within 11 days, Rhode had achieved $10 million in sales. One week following the launch, a fashion brand named Rhode co-founded by Purna Khatau and Phoebe Vickers filed a trademark infringement claim against Bieber, claiming her use of the name caused consumer confusion. A judge denied the motion "for a preliminary injunction without prejudice." In May 2025, Rhode announced it would be acquired by e.l.f. in a deal that consists of $800 million in cash and stock, with an additional $200 million based on future sales. The acquisition was completed in August. In April 2026, Rhode released the Rhode x The Biebers collaboration with Justin Bieber, introducing Spotwear hydrocolloid pimple patches alongside limited-edition versions of its Peptide Lip Treatment and Peptide Eye Prep.
=== Religion and schools === In 2019, Schmitt spoke in defense of the Cameron R-1 School District after it came under criticism from the Freedom From Religion Foundation over a high school football coach who led students in prayer before and after games. The group contended that the practice violating the Establishment Clause of the First Amendment. In a letter, Schmitt called the foundation an "extreme anti-religion organization" and said he would support the coach, school, and school district if the group sued.
The e-cigarette vapor is generated when the e-liquid is vaporized by the heating element or by other mechanical methods. The last step of vapor processing happens as the e-cigarette vapor passes through the main air passage to the user. For some advanced devices, before inhaling, the user can adjust the heating element temperature, air flow rate or other features. The liquid within the chamber of an e-cigarette is heated to roughly 100-250 °C to create an aerosolized vapor. This is thought to result in pyrolysis of the e-liquid and could also lead to decomposition of other liquid ingredients. The aerosol (mist) produced by an e-cigarette is commonly but inaccurately called vapor. In physics, a vapor is a substance in the gas phase whereas an aerosol is a suspension of tiny particles of liquid, solid or both within a gas. The power output of the e-cigarette is correlated to the voltage and resistance (P = V2/R, in watts), which is one aspect that impacts the production and the amount of toxicants of e-cigarette vapors. The power generated by the heating coil is not based solely on the voltage because it also relies upon the current, and the resultant temperature of the e-liquid relies upon the power output of the heating element. The production of vapor also relies upon the boiling point of the solvent. Propylene glycol boils at 188 °C, while glycerin boils at 290 °C. The higher temperature reached by glycerin may impact the toxicants emitted by the e-cigarette. The boiling point for nicotine is 247 °C.
=== Draft and debut === The Colorado Rockies selected Helton with the eighth overall pick of the 1995 Major League Baseball draft. He signed on August 1, 1995. He spent the next two years in the minor leagues, playing for the Class-A Asheville Tourists, Double-A New Haven Ravens, and Triple-A Colorado Springs Sky Sox before moving up to the majors. He made his major-league debut on August 2, 1997, a 6–5 road loss to the Pittsburgh Pirates. He started in left field, flied out in his first at-bat, singled in his next time up off Francisco Córdova, and hit a solo home run off Marc Wilkins.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.